Management of Pemphigus Herpetiformis
Pemphigus herpetiformis should be treated with systemic corticosteroids (prednisolone 0.5-1 mg/kg/day) combined with dapsone or sulfasalazine as the preferred first-line regimen, as this rare pemphigus variant responds particularly well to sulfonamide derivatives unlike other pemphigus forms.
First-Line Treatment Approach
While pemphigus herpetiformis (PH) is technically a pemphigus variant with intercellular IgG deposition, its management differs significantly from pemphigus vulgaris due to its unique therapeutic responsiveness.
Initial Therapy
Start with:
- Oral prednisolone 0.5-1 mg/kg/day (lower end of pemphigus dosing spectrum given PH tends to be milder) 1
- Dapsone 50-100 mg/day as the preferred adjuvant agent 2, 3
- Alternative: Sulfasalazine if dapsone is contraindicated
- Critical caveat: Check G6PD levels before starting dapsone to avoid hemolytic crisis
The evidence strongly supports sulfonamide derivatives as uniquely effective in PH. In a case series of 8 patients, all treated with dapsone or sulfasalazine achieved at least partial control 3. A 2016 case report demonstrated complete clinical remission with dapsone after initial corticosteroid/azathioprine therapy failed 2. This distinguishes PH from conventional pemphigus forms.
Rationale for This Approach
PH presents with pruritic urticarial plaques and vesicles (not the flaccid bullae of pemphigus vulgaris), often without mucosal involvement 4, 3. The neutrophil-predominant infiltrate and eosinophilic spongiosis on histology suggest a different pathomechanism that responds preferentially to dapsone's anti-neutrophil effects.
Second-Line Options
If dapsone/sulfasalazine plus corticosteroids fail after 4-6 weeks:
Consider switching to:
These conventional pemphigus adjuvants follow the British Association of Dermatologists guidelines for pemphigus vulgaris 1. One pediatric case achieved complete remission with azathioprine plus prednisone after dapsone failed 5, and a recent adult case responded to mycophenolate mofetil 4.
Corticosteroid Tapering Strategy
Once remission is achieved (no new lesions, healing of existing lesions):
- Taper prednisolone gradually over months
- Aim for ≤10 mg/day maintenance 1
- Do not taper prematurely: 47% relapse rate when stopped at 1 year 1
- Assess osteoporosis risk immediately and provide prophylaxis 1
Third-Line Therapies
For refractory cases unresponsive to above measures:
Rituximab appears INEFFECTIVE in PH - notably failed in 2 of 2 patients in one series 3, contrasting sharply with its 89% complete remission rate in pemphigus vulgaris 1. This is a critical distinction.
Consider instead:
- Intravenous immunoglobulin (IVIg) 2 g/kg divided over 5 days, monthly 1, 3
- Leflunomide - showed efficacy in 1 case 3
Key Clinical Pitfalls
Delayed diagnosis: PH evolves over time and initially mimics dermatitis herpetiformis clinically. Diagnosis requires high suspicion when pruritic urticarial plaques show intercellular IgG on direct immunofluorescence 3.
Acantholysis may be absent: Only 50% of PH cases show acantholysis on initial biopsy 3. Eosinophilic spongiosis with neutrophils is more characteristic.
Don't use rituximab early: Unlike pemphigus vulgaris where rituximab is now first-line in some guidelines, it appears ineffective in PH 3.
Mucosal involvement is rare but possible: When present (as in one 2026 case report 4), it doesn't change the treatment algorithm but may indicate more severe disease requiring higher corticosteroid doses.
Monitoring
- Clinical response: Expect improvement within 2-3 weeks of starting corticosteroids 1
- Peripheral eosinophilia: Present in 37.5% of cases, may track with disease activity 3
- Desmoglein antibodies: May be positive for Dsg1 and/or Dsg3 4, but titers lag behind clinical improvement 1
The prognosis is generally favorable with appropriate treatment, and PH tends to have a better course than pemphigus vulgaris, particularly when sulfonamide derivatives are utilized early 2, 3.